A model for predicting acute heart failure in patients with acute myocardial infarction by taking into account energy and adipokine metabolism indicators
DOI:
https://doi.org/10.26641/2307-0404.2022.3.265932Keywords:
adipokine, energy homeostasis, myocardial infarction, heart failure, prognosisAbstract
Acute heart failure (AHF) is one of the most common complications of acute myocardial infarction (AMI). Currently, adropin, irisin, fatty acid binding protein 4 (FABP 4) and C1q/TNF-binding protein 3 (CTRP 3) are considered to be valid markers of energy homeostasis and the adipokine system in AMI patients. The aim of the study was to predict the development of AHF in AMI patients by taking into account indicators of energy homeostasis and adipokine system using generalized linear mixed model. The study examined 189 patients with acute ST-segment elevation myocardial infarction. Concentrations of adropin, irisin, insulin, FABP4 and CTRP3 were determined by enzyme-linked immunosorbent assay. Fasting capillary blood glucose level was measured by glucoseoxidase method. Insulin resistance (IR) was assessed using homeostasis model assessment of insulin resistance (HOMA-IR). The study identified thrombolysis in myocardial infarction (TIMI) grade before intervention. A generalized linear mixed model was used to develop a method for predicting AHF in AMI patients. The study showed decreased levels of adropin, irisin and CTRP3 and increased levels of FABP4 in AMI patients. A mathematical model for predicting AHF development in AMI patients was proposed. The model consisted of fixed effects, namely, two one-factor indicators (HOMA-IR and systolic blood pressure (BP)), one two-factor indicator (systolic and diastolic BP) and one three-factor indicator (adropin, irisin and CTRP3) and random effects such as four one-factor indicators (FABP4, TIMI Grade Flow, platelets, total cholesterol). The accuracy of predicting the absence of Killip class I AHF was 100%, Killip class II AHF – 0%, Killip class III AHF – 11%, Killip class IV AHF – 82%. It should be noted that systolic BP on day 1 was a strong negative prognostic factor, while HOMA-IR, the combined effect of adropin, irisin and CTRP3, the combined effect of systolic and diastolic BP were positive prognostic factors. Thus, the model showed a very high sensitivity in predicting Killip class IV AHF. The overall accuracy of the model was 89.4%.
References
Zaremba YeKh, Salo VM, Myzak YaV, Zaremba OV. [Clinical course of acute myocardial infarction complicated by acute left ventricular failure after coronary angio¬graphy with stenting]. Family medicine. 2016;3:30-32. Ukr. doi: https://doi.org/10.30841/2307-5112.3(65).2016.79966
Kravchun PH, Shaparenko OV. [Irisin as a marker of insulin resistance in patients with hypertension and obesity]. Actual problems of modern medicine: Bulletin of Ukrainian medical stomatological academy. 2018;18(1):68-70. Ukrainian. Available from: http://elib.umsa.edu.ua/bitstream/umsa/11045/1/ Kravchun_Irisin_as_a_marker_ of_insulin_resistance_in_patients.pdf
Kupnovytska IG, Ersteniuk AM. [Laboratory diagnostics]. Vinnytsia: Nova Knyha; 2017. Ukrainian.
Solomonchuk AV, Rasputina LV. [Prevalence dynamics, sex-age characteristics and mortality in acute heart failure in patients with myocardial infarction]. Reports of Vinnytsia national medical university. 2020;24(2):303-8. Ukrainian.
doi: http://doi.org/10.31393/reports-vnmedical-2020-24(2)-18
Abd El-Mottaleb N, Galal HM, El Maghraby KMA, Gadallah AI. Serum irisin level in myocardial infarction patients with or without heart failure. Canadian Journal of Physiology and Pharmacology. 2019;97(10). doi: http://doi.org/10.1139/cjpp-2018-0736
Ertem AG, Unal S, Efe TH, Acar B, Yayla C, Kuyumcu MS, et al. Association between serum adropin level and burden of coronary artery disease in patients with non-ST elevation myocardial infarction. Anatolisn journal of cardiology. 2017;17(2):119-24. doi: http://doi.org/10.14744/AnatolJCardiol.2016.7149
Yildirim A, Sumbul HE, Koca H, Kucukos¬ma-noglu M, Icen YK, Koc M. Complement C1q/tumor nec-rosis factor-related protein-3 (CTRP3) is significantly decreased in patients with heart failure and closely related with ventricular tachycardia. Acta Cardiologica Sinica. 2021;37(3):278-85. doi: http://doi.org/10.6515/ACS.202105_37(3).20201019B
Obokata M, Iso T, Ohyama Y, Sunaga H, Kawaguchi T, Matsui H, et al. Early increase in serum fatty acid binding protein 4 levels in patients with acute myocardial infarction. European Heart Journal: Acute Cardiovascular Care. 2016;7(6):561-9. doi: http://doi.org/10.1177/2048872616683635
Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal. 2018;39(2):119-77. doi: http://doi.org/10.1093/eurheartj/ehx393
Rodríguez-Calvo R, Girona J, Alegret JM, Bos-quet A, Ibarretxe D, Masana L. Role of the fatty acid-binding protein 4 in heart failure and cardiovascular disease. Journal of Endocrinology. 2017;233(3):R173-84. doi: http://doi.org/10.1530/joe-17-0031
Shen S, Gao R, Bei Y, Li J, Zhang H, Zhou Y, et al. Serum irisin predicts mortality risk in acute heart failure patients. Cellular Physiology and Biochemistry. 2017;42(2):615-22. doi: http://doi.org/10.1159/000477867
Shelest BO. Hypertension grade influence on inflammation and adropin level in diabetic patients with obesity. Ukrainian Journal of medicine, biology and sport. 2019;4(5):244-8.
doi: http://doi.org/10.26693/ jmbs04.05.244
Si Y, Fan W, Sun L. A review of the relationship between CTRP family and coronary artery disease. Current Atherosclerosis Reports. 2020;22(6):22. doi: http://doi.org/10.1007/s11883-020-00840-0
Stroup WW, Milliken GA, Claassen EA, Wolfinger RD. SAS for mixed models: introduction and basic applications. Cary, NC: SAS Institute; 2018.
Syvolap VD, Kapshуtar NI. Predictors of acute heart failure in patients during the acute period of Q-wave myocardial infarction. Zaporozhye medical journal. 2019;21(2):160-4.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Medicni perspektivi
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.